Effect of the combined treatment of chidamide and crizotinib on the growth of HCC827-derived tumor xenografts in Balb/c nude mice. (A) The growth status of HCC827 xenografts in mice treated with chidamide, crizotinib, or their combination (n=10) on the 21st day of treatment. Balb/c nude mice bearing established HCC827-derived tumors were treated with vehicle, chidamide (5 mg/kg/d), crizotinib (25 mg/kg/d) or drug combinations by intragastric administration daily for 21 days. (B) Tumor volumes in different groups. (C) Body weights of mice in different groups. */**/***, P <0.05/0.01/0.001.